CHEKOV: CHEcKpoint Inhibitor effects On SARS-CoV-2 Vaccination
Chekov:CHEcKpoint 抑制剂对 SARS-CoV-2 疫苗接种的影响
基本信息
- 批准号:MR/W01615X/1
- 负责人:
- 金额:$ 7.08万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2021
- 资助国家:英国
- 起止时间:2021 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The immune system of cancer patients is affected by their disease but also from side effects of their treatment. A new class of anti-cancer drugs, immune checkpoint inhibitors (ICIs), are very different to all other treatments because they work by directly altering the immune system to target the cancer. These drugs are now used routinely to treat patients with various cancers. They can also cause side effects that could be enhanced by SARS-CoV2 infection or vaccination. There is very little known about how ICIs impact vaccination against SARS-CoV-2. Given that COVID-19 is likely to circulate for the foreseeable future, it is important to know if current COVID-19 vaccines are effective in patients receiving ICIs. To address this question, we have been collecting blood samples from melanoma patients being treated with ICIs that were infected during the pandemic. More recently we collected samples from ICI-treated melanoma patients and healthy individuals during the COVID-19 vaccination campaign. We now wish to test these samples to see if vaccination of ICI-treated patients illicits the same magnitude and quality of immune response as observed in healthy individuals, or if different vaccines and/or different vaccine scheduling may be required to protect these patients. We will also examine if vaccination or infection of patients receiving ICIs could increase the risk of developing the immune-driven side effects that can be caused by these drugs.
癌症患者的免疫系统不仅受到自身疾病的影响,也受到治疗副作用的影响。一类新的抗癌药物,免疫检查点抑制剂(ICIs),与所有其他治疗方法非常不同,因为它们通过直接改变免疫系统来靶向癌症。这些药物现在被常规用于治疗各种癌症患者。它们还会引起副作用,这些副作用可能会因感染SARS-CoV2或接种疫苗而增强。关于ICIs如何影响针对SARS-CoV-2的疫苗接种,我们知之甚少。鉴于COVID-19可能在可预见的未来传播,了解目前的COVID-19疫苗对接受ici的患者是否有效非常重要。为了解决这个问题,我们一直在收集大流行期间感染的接受ICIs治疗的黑色素瘤患者的血液样本。最近,我们在COVID-19疫苗接种运动期间从ci治疗的黑色素瘤患者和健康个体中收集了样本。我们现在希望对这些样本进行测试,以了解接种ici治疗的患者是否会产生与健康人相同的免疫反应强度和质量,或者是否需要不同的疫苗和/或不同的疫苗接种计划来保护这些患者。我们还将检查是否接种疫苗或感染接受ICIs的患者可能会增加这些药物引起的免疫驱动副作用的风险。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Graham Taylor其他文献
Prostaglandins : biology and chemistry of prostaglandins and related eicosanoids
前列腺素:前列腺素和相关类二十烷酸的生物学和化学
- DOI:
- 发表时间:
1988 - 期刊:
- 影响因子:0
- 作者:
Graham Taylor - 通讯作者:
Graham Taylor
Compact modeling of high-dimensional time-series
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Graham Taylor - 通讯作者:
Graham Taylor
Properties and units in the clinical laboratory sciences part XXIV. Properties and units in clinical molecular genetics (technical report 2017)
- DOI:
10.1016/j.cca.2018.05.028 - 发表时间:
2018-09-01 - 期刊:
- 影响因子:
- 作者:
Ulla M. Petersen;Ariadna Padró-Miquel;Graham Taylor;Jens Michael Hertz;Rebecca Ceder;Xavier Fuentes-Arderiu;Johan T. den Dunnen - 通讯作者:
Johan T. den Dunnen
Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
- DOI:
10.1186/1742-4690-11-s1-p8 - 发表时间:
2014-01-07 - 期刊:
- 影响因子:3.900
- 作者:
Huseini Kagdi;Paul Fields;Andrew Hodson;Graham Taylor - 通讯作者:
Graham Taylor
Molecular characterization of heterogeneity in adult T-cell leukaemia/lymphoma
- DOI:
10.1186/1742-4690-12-s1-p69 - 发表时间:
2015-08-28 - 期刊:
- 影响因子:3.900
- 作者:
Huseini Kagdi;Aileen Rowan;Maria Antoinietta Demontis;Charles Bangham;Graham Taylor - 通讯作者:
Graham Taylor
Graham Taylor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Graham Taylor', 18)}}的其他基金
Early detection and evaluation of HTLV-1-associated neuro-inflammation and damage
HTLV-1相关神经炎症和损伤的早期检测和评估
- 批准号:
MR/X022358/1 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Research Grant
Mechanisms of endogenous antigen processing by the MHC class II pathway: studies with viral and cellular proteins
MHC II 类途径内源性抗原加工的机制:病毒和细胞蛋白的研究
- 批准号:
G0801936/1 - 财政年份:2009
- 资助金额:
$ 7.08万 - 项目类别:
Research Grant
Pathogenesis of HTLV-I-associated inflammation: Exploration through therapeutic intervention
HTLV-I 相关炎症的发病机制:通过治疗干预进行探索
- 批准号:
G0401616/1 - 财政年份:2006
- 资助金额:
$ 7.08万 - 项目类别:
Research Grant
相似国自然基金
NK细胞抑制性受体CD96作为肝癌checkpoint免疫治疗靶点的进一步验证
- 批准号:81972679
- 批准年份:2019
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Pre-clinical development of a live biotherapeutic product engineered to remodel hyaluronic acid in solid tumours to enable checkpoint inhibitor efficacy
一种活体生物治疗产品的临床前开发,旨在重塑实体瘤中的透明质酸,以实现检查点抑制剂的功效
- 批准号:
10078115 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Collaborative R&D
Enhancing triple negative breast cancer response to immune checkpoint inhibitor therapy via targeted therapies
通过靶向治疗增强三阴性乳腺癌对免疫检查点抑制剂治疗的反应
- 批准号:
10607065 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Elucidation of new mechanism of acquiring resistance to Immune checkpoint inhibitor
阐明获得免疫检查点抑制剂耐药性的新机制
- 批准号:
23KJ1108 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Characterization of Altered Immunity in Patients with Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy
免疫检查点抑制剂治疗引起的炎症性关节炎患者免疫改变的特征
- 批准号:
10885381 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity
免疫检查点抑制剂治疗引起的结肠毒性的路径引导治疗
- 批准号:
10752985 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Gaining Insights Into Immune Checkpoint Inhibitor Associated Inflammatory Arthritis Using Administrative Data
使用管理数据深入了解免疫检查点抑制剂相关的炎症性关节炎
- 批准号:
495130 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Operating Grants
Predictive modeling of cutaneous immune checkpoint inhibitor toxicities
皮肤免疫检查点抑制剂毒性的预测模型
- 批准号:
10590369 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
REsolving Seronegative and CheckpOint inhibitor-induced iNflammatory ArthriTis by synovial dEconstruction (RESONATE)
通过滑膜解构 (RESONATE) 解决血清阴性和检查点抑制剂诱导的炎症性关节炎
- 批准号:
MR/X02914X/1 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Research Grant
Activated T cell PET imaging for the evaluation of checkpoint inhibitor immunotherapy
活化 T 细胞 PET 成像用于评估检查点抑制剂免疫疗法
- 批准号:
23K14865 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events
揭示检查点抑制剂免疫相关不良事件基本机制的系统方法
- 批准号:
10637272 - 财政年份:2023
- 资助金额:
$ 7.08万 - 项目类别: